Evidence map›Paper›PMID 33347434›Full record

ArticlePLoS biology2020

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins.

Carina Conceicao, Nazia Thakur, Stacey Human, James T Kelly, Leanne Logan, Dagmara Bialy, Sushant Bhat, Phoebe Stevenson-Leggett, Adrian K Zagrajek, Philippa Hollinghurst and 13 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PLoS biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed
4.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 218 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Carina ConceicaoThe Pirbright Institute, Woking, Surrey, United Kingdom.
Nazia ThakurThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-4450-5911
Stacey HumanThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0003-4735-2065
James T KellyThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-8307-507X
Leanne LoganThe Pirbright Institute, Woking, Surrey, United Kingdom.
Dagmara BialyThe Pirbright Institute, Woking, Surrey, United Kingdom.
Sushant BhatThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0003-1869-6176
Phoebe Stevenson-LeggettThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-6509-3354
Adrian K ZagrajekThe Pirbright Institute, Woking, Surrey, United Kingdom.
Philippa HollinghurstThe Pirbright Institute, Woking, Surrey, United Kingdom.
Michal VargaThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-7437-1723
Christina TsirigotiThe Pirbright Institute, Woking, Surrey, United Kingdom.
Matthew TullyThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-1395-1775
Chris ChiuThe Pirbright Institute, Woking, Surrey, United Kingdom.
Katy MoffatThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0003-0120-7196
Adrian Paul SilesianThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-4100-9269
John A HammondThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-2213-3248
Helena J MaierThe Pirbright Institute, Woking, Surrey, United Kingdom.
Erica BickertonThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-4012-1283
Holly SheltonThe Pirbright Institute, Woking, Surrey, United Kingdom.
Isabelle DietrichThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-6300-109X
Stephen C GrahamDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-4547-4034
Dalan BaileyThe Pirbright Institute, Woking, Surrey, United Kingdom.ORCID 0000-0002-5640-2266
The Pirbright Institute · GBUniversity of Cambridge · GB

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007034Biotechnology and Biological Sciences Research Council BBS/E/I/00007037Biotechnology and Biological Sciences Research Council BBS/E/I/00007038Biotechnology and Biological Sciences Research Council BBS/E/I/00007039Biotechnology and Biological Sciences Research Council BBS/E/I/COV07001Medical Research Council MR/P021735/1Wellcome TrustWellcome Trust 098406/Z/12/B
6 · The paper itself

Abstract

SARS Coronavirus 2 (SARS-CoV-2) emerged in late 2019, leading to the Coronavirus Disease 2019 (COVID-19) pandemic that continues to cause significant global mortality in human populations. Given its sequence similarity to SARS-CoV, as well as related coronaviruses circulating in bats, SARS-CoV-2 is thought to have originated in Chiroptera species in China. However, whether the virus spread directly to humans or through an intermediate host is currently unclear, as is the potential for this virus to infect companion animals, livestock, and wildlife that could act as viral reservoirs. Using a combination of surrogate entry assays and live virus, we demonstrate that, in addition to human angiotensin-converting enzyme 2 (ACE2), the Spike glycoprotein of SARS-CoV-2 has a broad host tropism for mammalian ACE2 receptors, despite divergence in the amino acids at the Spike receptor binding site on these proteins. Of the 22 different hosts we investigated, ACE2 proteins from dog, cat, and cattle were the most permissive to SARS-CoV-2, while bat and bird ACE2 proteins were the least efficiently used receptors. The absence of a significant tropism for any of the 3 genetically distinct bat ACE2 proteins we examined indicates that SARS-CoV-2 receptor usage likely shifted during zoonotic transmission from bats into people, possibly in an intermediate reservoir. Comparison of SARS-CoV-2 receptor usage to the related coronaviruses SARS-CoV and RaTG13 identified distinct tropisms, with the 2 human viruses being more closely aligned. Finally, using bioinformatics, structural data, and targeted mutagenesis, we identified amino acid residues within the Spike-ACE2 interface, which may have played a pivotal role in the emergence of SARS-CoV-2 in humans. The apparently broad tropism of SARS-CoV-2 at the point of viral entry confirms the potential risk of infection to a wide range of companion animals, livestock, and wildlife.

Indexed as

Viral TropismVirus AttachmentAmino Acid SubstitutionAngiotensin-Converting Enzyme 2AnimalsBinding SitesCatsCattleDogsGuinea PigsHEK293 CellsHost-Pathogen InteractionsHumansRabbitsRatsSARS-CoV-2Angiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID33347434
PMCPMC7751883
OpenAlexW3117882848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.